--First data disclosure from Ribometrix’s RNA-targeting drug discovery platform identifies small molecules targeting c-MYC, a validated but historically undruggable cancer driver -- --Data shows ...
The c-Myc oncoprotein is frequently overexpressed in human cancers and is essential for cancer cell proliferation. The dysregulation of ubiquitin-proteasome-mediated degradation is one of the ...
Preliminary safety and activity of perioperative triplet chemotherapy plus bevacizumab (bev) in patients with borderline resectable colorectal cancer liver metastases (CLM). Final phase II trial ...
The Innovation Center of NanoMedicine reported in ACS Nano together with the group of Prof. Yu Matsumoto of Otorhinolaryngology and Head and Neck Surgery and the group of Prof. Horacio Cabral of the ...
So, what insight are we left with? “On the highest level,” notes Dr. Eisenman, “this study really demonstrates that a single amino acid substitution in a single protein is enough to predispose the ...
Scientists at the Karolinska Institutet in Sweden have found a new region in the c-Myc oncogene that would allow the development of a binding compound to target it. Their discovery is based on a ...
The Innovation Center of NanoMedicine (Director General: Prof. Kazunori Kataoka, Location: Kawasaki in Japan, Abbreviation: iCONM) reported in ACS Nano (Impact Factor: 14.588 in 2019) together with ...
Scientists at Lund University have discovered how E. coli bacteria target and degrade the well-known oncogene MYC, which is involved in many forms of cancer. The study is now published in Nature ...
February 26, 2021 - Kawasaki, Japan: The Innovation Center of NanoMedicine (Director General: Prof. Kazunori Kataoka, Location: Kawasaki in Japan, Abbreviation: iCONM) reported in ACS Nano (Impact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results